- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| Mi | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 128 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| Mi | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Di | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 315 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 23.03. | MAIA Biotechnology, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 03.03. | MAIA Biotechnology slides after pricing offering to raise $30M | 2 | Seeking Alpha | ||
| 03.03. | MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down | 2 | RTTNews | ||
| 03.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock | 212 | GlobeNewswire (Europe) | Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA"... ► Artikel lesen | |
| 02.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants | 139 | GlobeNewswire (Europe) | CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies... ► Artikel lesen | |
| 24.02. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.02. | MAIA Biotechnology, Inc.: MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market | 375 | GlobeNewswire (Europe) | Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine... ► Artikel lesen | |
| 20.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 509 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen | |
| 13.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.12.25 | MAIA Biotechnology, Inc.: MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 371 | GlobeNewswire (Europe) | Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA)... ► Artikel lesen | |
| 16.12.25 | MAIA Biotechnology announces $1.51M private placement | 2 | Seeking Alpha |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 118,00 | -0,46 % | BREAKING: Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München | Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die milliardenschwere Übernahme von Soleno Therapeutics... ► Artikel lesen | |
| ABBVIE | 177,50 | +0,06 % | RBC Capital reiterates Abbvie stock Outperform rating at $260 target | ||
| ABBOTT LABORATORIES | 85,58 | +0,09 % | Abbott survey finds 'information overload, confusion and cost' affecting health choices in US | ||
| SCHOTT PHARMA | 13,920 | +1,75 % | Schott Pharma: Ausblick auf die Quartalszahlen | Am 13. Mai wird es bei Schott Pharma Zahlen zum zweiten Quartal geben. Die Analysten der Deutschen Bank rechnen mit einem organischen Umsatzplus von 1 Prozent. Das bereinigte EBITDA soll um 6 Prozent... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 66,54 | +0,21 % | Edwards Lifesciences Corp. Q4 Profit Falls | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) announced earnings for fourth quarter that Drops, from last yearThe company's earnings totaled $91.2 million, or $0.16 per share. This... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 24,450 | +0,82 % | Assembly Biosciences vor ESCMID-Auftritt: Ab ins Rampenlicht | Mein Biotech-Favorit Assembly Biosciences rückt zunehmend in den Fokus der internationalen Wissenschafts- und Investorengemeinde. Das Unternehmen kündigte an, mehrere Datensätze aus jüngsten Proof-of-Concept-Studien... ► Artikel lesen | |
| PENTIXAPHARM | 2,070 | +0,49 % | EQS-News: Pentixapharm Holding AG beruft Erik Merten in den Vorstand | EQS-News: Pentixapharm Holding AG
/ Schlagwort(e): Personalie
Pentixapharm Holding AG beruft Erik Merten in den Vorstand
31.03.2026 / 08:00 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,442 | +1,12 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 151,00 | 0,00 % | UBS raises Axsome Therapeutics price target on Auvelity outlook | ||
| MEDPACE | 415,90 | -1,21 % | Zelluna ASA: Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial | Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA... ► Artikel lesen | |
| ZEALAND PHARMA | 38,510 | +0,23 % | Resolutions from Zealand Pharma's Annual General Meeting 2026 | Company announcement - No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| UNITED THERAPEUTICS | 485,60 | 0,00 % | Raymond James stuft United Therapeutics mit "Outperform" ein - Kursziel 700 Dollar | ||
| UCB | 274,30 | -0,15 % | UCB SA Reports Long-Term Bimzelx Data In Hidradenitis Suppurativa | BRUSSELS (dpa-AFX) - UCB S.A. (UCBJY) announced on Friday that it has presented new post hoc data regarding Bimzelx (bimekizumab) at the American Academy of Dermatology Annual Meeting 2026 held... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 437,50 | -1,31 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| BRIDGEBIO PHARMA | 64,12 | +0,83 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,250 Euro und damit +6,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.